



Reply to: Cause or consequence?

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 14 Jan 2022
Accepted: 19 Jan 2022



Reply to F.M. Volpe:

We thank F.M. Volpe for questioning whether the results of the SABINA III study showing associations between short-acting β_2 -agonist (SABA) prescriptions and poor asthma outcomes should be regarded as “cause or consequence.” We agree that causation cannot be assumed and stated this clearly as follows “this cross-sectional study does not permit an assessment of a causal link between SABA prescriptions and asthma outcomes and does not discount reverse causality; the results simply represent an association” [1]. But implying that high levels of SABA use is simply a “consequence” is also an oversimplification of a complex issue. First, besides the consistent results from epidemiological studies, there are many mechanistic studies of the negative effects of regular SABA use on biomarkers of airway inflammation, airway hyper-responsiveness, asthma symptom control and exacerbation risk, so causation is not ruled out [2, 3]. Further, while logical to consider that high use of an as-needed medication for symptoms must represent poor control, we would point out that a central purpose of our paper was to assess not inhaler use, but SABA prescriptions by clinicians and purchase over the counter. These are systemic issues concerning physician behaviour and access to SABAs that, in the face of excessive use and poor asthma control, permit or even encourage SABA use, which is contrary to asthma guideline recommendations [4]. The “long list” of recommendations for addressing this situation is therefore highly pertinent to the objectives of the paper and we agree that these may, and in fact are intended to, have “profound implications... for clinical practice and public health” [4–6].

Shareable abstract (@ERSpublications)

SABINA III shows associations between SABA prescriptions and poor asthma outcomes and does not imply causation. However, implying that high SABA use is simply a “consequence” of poor asthma control is also an oversimplification of a complex issue. <https://bit.ly/3rXKSGm>

Cite this article as: Bateman ED, Price DB, Wang H-C, *et al.* Reply to: Cause or consequence? *Eur Respir J* 2022; 59: 2200103 [DOI: 10.1183/13993003.00103-2022].

Eric D. Bateman¹, David B. Price^{2,3}, Hao-Chien Wang⁴, Patricia Schonfeldt⁵, Angelina Catanzariti⁶, Ralf J.P. van der Valk⁷ and Maarten J.H.I. Beekman⁸

¹Division of Pulmonology, Dept of Medicine, University of Cape Town, Cape Town, South Africa.

²Observational and Pragmatic Research Institute, Singapore. ³Centre of Academic Primary Care, Division of Applied Sciences, University of Aberdeen, Aberdeen, UK. ⁴Dept of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. ⁵Especialista Medicina Interna y Enfermedades Respiratorias, Instituto Nacional del Tórax ITMS Telemedicina de Chile, Santiago, Chile. ⁶AstraZeneca, Sydney, Australia. ⁷AstraZeneca, Cambridge, UK. ⁸AstraZeneca, The Hague, The Netherlands.

Corresponding author: Eric D. Bateman (eric.bateman@uct.ac.za)

Conflict of interest: E.D. Bateman is a member of the Science Committee and Board of GINA and reports personal fees from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, Menarini, Novartis, Orion, Regeneron Pharmaceuticals and Sanofi Genzyme. D.B. Price has board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Regeneron, Sanofi Genzyme, Teva Pharmaceuticals and Thermofisher; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline (GSK), Mylan, Mundipharma, Novartis, Pfizer, Teva and Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Pfizer, Regeneron, Respiratory Effectiveness Group, Sanofi Genzyme, Teva, Theravance and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kyorin, Mylan, Mundipharma, Novartis, Regeneron, Sanofi Genzyme and Teva; payment for the development of educational materials from Mundipharma and Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim,

Mundipharma, Mylan, Novartis and Thermofisher; funding for patient enrolment or completion of research from Novartis; stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); is a peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme and Health Technology Assessment; and was an expert witness for GSK. H-C. Wang reports no disclosures. P. Schonfeldt reports lectures on medical education and inclusion as a researcher on clinical study protocols funded by AstraZeneca, GSK, Teva, ITF Labomed, Boehringer Ingelheim and Sanofi Genzyme. A. Catanzariti and R.J.P. van der Valk are employees of AstraZeneca. R.J.P. van der Valk has shares in GSK and shares and options in AstraZeneca. M.J.H.I. Beekman was an employee of AstraZeneca at the time the study was conducted and has shares in AstraZeneca.

Support statement: AstraZeneca funded the SABINA III study; was involved in the study design, protocol development, study conduct and statistical analysis; and was given the opportunity to review this manuscript before submission. Publication support was provided by Michelle Rebello of Cactus Life Sciences and funded by AstraZeneca. Funding information for this article has been deposited with the Crossref Funder Registry.

References

- 1 Bateman ED, Price DB, Wang HC, *et al.* Short-acting β_2 -agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. *Eur Respir J* 2022; 59: 2101402.
- 2 Hancox RJ, Cowan JO, Flannery EM, *et al.* Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. *Respir Med* 2000; 94: 767–771.
- 3 Aldridge RE, Hancox RJ, Taylor DR, *et al.* Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. *Am J Respir Crit Care Med* 2000; 161: 1459–1464.
- 4 Reddel HK, FitzGerald JM, Bateman ED, *et al.* GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. *Eur Respir J* 2019; 53: 1901046.
- 5 Hills R, Beasley R. The history and future of short-acting beta2-agonist therapy in asthma. *Respirology* 2020; 25: 246–248.
- 6 Nannini LJ, Luhning S, Rojas RA, *et al.* Position statement: asthma in Latin America. Is short-acting beta-2 agonist helping or compromising asthma management? *J Asthma* 2021; 58: 991–994.